Vision

To be a relevant actor in the implementation of research programs, whose results provide solutions to relevant problems in the area of human health.

Mission

To carry out technological research in the area of human health with applicability and impact in the productive sector.

Promote University-Industry alliances.

Creation of permanent research capacities through:

  • Training highly qualified staff to contribute to research in the university and the industry.

  • Creation of infrastructure and acquisition of state-of-the-art equipment for research.

     

    BACKGROUND

    BMRC, Biomedical Research Consortium-Chile

    BMRC, Biomedical Research Consortium-Chile was set up in 2007 as the result of the association between the Pontificia Universidad Católica de Chile, Recalcine Pharmaceutical Corporation and other important companies in the pharmaceutical area. The objective of this alliance between the private company and the Academy is to develop and generate solutions (product/ technological package) with a high impact on human health through R & D lines, applicable and transferable to the market.

    Today the consortium consists of the Universidad Católica and Abbott, a US-based pharmaceutical laboratory that acquired Recalcine as an instrument to access the Latin American market. Both institutions finance the activities of the consortium.

    Other relevant actors are a team of six researchers sponsored by the consortium, leaders in their respective areas, with wide national and international recognition, as well as important alliances and collaborations with important research centers in the rest of the world. Finally, the State contributes public funds to the initiative through Corfo, which has replaced the original instrument by Conicyt: Bicentennial Program for Science and Technology. II Business Technological Consorsiums in Research 2005.

    The consortium's governance is as follows: an executive team; a board of directors representing the members of the consortium (UC-Abbott); technical, executive and commercial committees; external advisors; and five researchers.